An update from Tonix Pharma (TNXP) is now available.
Tonix Pharmaceuticals has published research indicating that their product, TNX-102 SL, may offer short-term benefits for military-related PTSD, specifically in improving symptoms and sleep quality when administered at bedtime. This finding, which is still in the early phase 3 trial stage, opens up the possibility of using TNX-102 SL in the immediate aftermath of traumatic events for those affected by PTSD. Investors should note that these are forward-looking statements subject to risks and uncertainties, and actual results could differ materially.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
